<DOC>
	<DOCNO>NCT01871285</DOCNO>
	<brief_summary>The primary aim study determine chronic pain subject around-the-clock opioids receive 100 220 mg oral morphine sulfate equivalent ( MSE ) safely transition buprenorphine hydrochloride ( HCl ) buccal film 50 % MSE dose without induce opioid withdrawal reverse analgesic effect .</brief_summary>
	<brief_title>Evaluation Tolerability Switching Subjects Chronic ATC Opioid Therapy Buprenorphine HCl Buccal Film</brief_title>
	<detailed_description />
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>1 . Written inform consent obtain prior studyrelated procedure perform 2 . Male nonlactating female subject 18 60 year age time consent 3 . Female subject nonpregnant basis screen serum pregnancy test practice abstinence use medically acceptable form contraception ( eg , intrauterine device , hormonal birth control , double barrier method ) postmenopausal , biologically sterile , surgically sterile ( ie , hysterectomy , bilateral oophorectomy , tubal ligation ) 1 year 4 . Male subject practice abstinence , surgically sterile use medically acceptable form contraception 5 . Subjects ≥6 month history chronic pain ( include peripheral neuropathic pain ) require ATC opioid therapy ≥80 mg ≤220 mg MSE per day least 28 day 6 . Receiving one follow opioids ATC ≥28 day : ( ) Morphine Sulfate ; ( ii ) Oxycodone hydrochloride 7 . Displays sign symptom withdrawal ( ie , COWS score ≥5 ) within 5 minute follow naloxone challenge 8 . Able understand study procedure , complete assessment scale , communicate meaningfully study personnel 9 . Stable health , determine Principal Investigator , basis medical history , physical examination , screen laboratory result 1 . Inability meet study participation requirement , include two 2night stay pharmacokinetic sample 2 . A history current evidence clinically significant pulmonary ( eg , asthma , chronic obstructive pulmonary disease , cor pulmonale severe bronchial asthma ) , gastrointestinal , hepatic , renal , hematologic , immunologic , endocrine , neurologic , oncologic psychiatric disorder condition , include evidence abnormality physical examination , abnormal vital sign , electrocardiogram ( ECG ) , clinical laboratory value opinion Investigator , would jeopardize safety subject impact validity study result 3 . Supine systolic blood pressure &gt; 180 mm Hg &lt; 90 mm Hg diastolic blood pressure &gt; 105 mm Hg &lt; 50 mm Hg screening ( may repeat ) 4 . COWS score great 4 prior screen naloxone challenge 5 . Aspartate aminotransferase alanine aminotransferase &gt; 3 time upper limit normal serum creatinine &gt; 1.9 mg/dL Screening , laboratory abnormality , opinion Investigator , would contraindicate study participation 6 . Use monoamine oxidase inhibitor within 14 day screen study 7 . Use medication , nutraceutical herbal product cytochrome P450 3A4 inhibition induction property within past 30 day 8 . Donation 450 mL blood within 30 day prior screen hemoglobin value &lt; 11.0 g/dL screen 9 . Documented history alcohol and/or substance abuse ( exclude nicotine and/or caffeine ) within 5 year prior screen , and/or currently treatment seek treatment alcohol and/or substance abuse , assess Diagnostic Statistical Manual Mental Disorders ( DSMIVTR ) criteria 10 . Positive alcohol breath test screen 11 . Positive urine toxicology screen drug abuse screen 12 . History hypersensitivity , allergy , contraindication opioid clinically significant intolerance buprenorphine naloxone 13 . History seizure , convulsion , increase intracranial pressure ( history pediatric febrile seizure permit ) 14 . History significant head injury within 6 month screen 15 . Any clinically significant abnormality buccal mucosa could impact drug absorption 16 . Participation treatment phase clinical research study involve investigational drug within 28 day ( 5 elimination halflives , whichever long ) screen 17 . Previous participation clinical study clinical study involve BEMA buprenorphine ( buprenorphine HCl buccal film ) 18 . In Investigator 's opinion significant risk suicidal behavior base Columbia Suicide Severity Rating Scale ( CSSRS ) 19 . Hypokalemia clinically unstable cardiac disease , include unstable atrial fibrillation , symptomatic bradycardia , unstable congestive heart failure , active myocardial ischemia 20 . History myocardial infarction 21 . Corrected QT interval ( QTcF ) ≥450 millisecond 12lead ECG 22 . History long QT syndrome family member condition 23 . Use class IA antiarrhythmic medication class III antiarrhythmic medication within 14 day screen 24 . Current use α2 agonist antihypertensive ( eg , clonidine ) , 5HT3 antagonist ( eg , ondansetron ) , benzodiazepine , medication would anticipate confound detection sign symptom opioid withdrawal 25 . Involvement plan and/or conduct study ( applies sponsor designee staff staff study site )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ATC , Opioid , withdrawal , switch</keyword>
</DOC>